2024-03-31 19:26 Economic Daily Reporter Xie Baihong/Reporting in real time The new plant drug “Dou Zhi Xiang” from “Subi Yi”.Picture/provided in one
Heyi (4743) recently held its first quarter legal conference of this year, and the new drug “Subiyi” for diabetic foot ulcers is gradually bearing fruit in domestic and overseas markets. United Biotechnology stated that “Subyi” has entered the three major domestic medical center systems of National Taiwan University, Taipei Wing General Hospital and Chang Gung Memorial Hospital in the first quarter of this year. In the overseas market, Singapore has also been officially shipped since March. The next step is for mainland China in 7 this year. Starting from this month, we will also seek mainland medical insurance approval.
Zheng Shuling, general manager of Heyi, said that this year is the business year of Heyi. After “Subiyi” obtained the mainland’s new drug certificate in the fourth quarter of 2023, it will officially enter the commercialization stage from the research and development stage. Heyi will open the door to the global market with a dual-track strategy of innovative drugs and medical materials. In terms of innovative drugs, “Fespixon” has been approved for marketing in Taiwan, Singapore, Malaysia and mainland China; Indonesia, the Philippines and Vietnam are entering substantive review.
In terms of medical materials, Bonvadis medical materials have obtained general wound and scar medical material licenses from the United States, the European Union, India, New Zealand, South Africa, Egypt, Thailand, and Pakistan. In the second phase, multi-country applications for chronic wound medical material licenses will be submitted as planned. It is expected to be listed on major global markets this year and next year.
United Biotechnology explained that after obtaining the National Health Insurance Validation Price in Taiwan last year, “Subyi” has started to be distributed in the three major systems of National Taiwan University Hospital, Taipei Wing General Hospital, and Chang Gung Memorial Hospital in the first quarter of this year. In addition to having diabetes, “Subyi” In addition to the clinical evidence of foot ulcers, many doctors have already used “Subyi” to treat more refractory wounds and acute wounds.
Zheng Shuling said that the mainland market of “Subi Yi” will adopt the exclusive authorized general distribution method. Currently, it is still discussing cooperation with a number of large pharmaceutical companies with national sales channels. Some investors have inquired about whether Heyi will cooperate with China Resources Double Crane Pharmaceuticals of China. Heyi has not directly responded to the rumors of cooperation. Heyi emphasized that the annual medical insurance negotiations in mainland China from July to December every year will be the next important market key point for “Subiyi”.
United Biotechnology stated that the Fespixon Singapore market has signed a contract with local distributors in February this year, and the first batch of drugs has entered Singapore in March. There are currently about 70,000 diabetic foot ulcer patients in Singapore. The legal person estimates that in the future, it can provide The integration brings more than US$46 million in market opportunities. Malaysia is currently in the contract negotiation stage with local distributors, and large local hospitals have made purchase requests.
For the U.S. market, Bonvadis has obtained a medical material license for general wound indications. In the second phase, it is adding chronic wound indications for a trial plan to expand clinical feedback for different indications such as podiatry, dermatology, and surgery. In addition, the integrated Bonvadis has also received orders from Egypt and is waiting for the regional distribution contract to be signed before shipments can begin.
In-One Medical Materials Diabetes
Further reading
2024-03-31 11:26:24
#quarter #Heyi #Subiyi #successfully #entered #major #medical #centers #Taiwan #Singapore #market
